[go: up one dir, main page]

ZA894665B - Immunoconjugates for cancer diagnosis and therapy - Google Patents

Immunoconjugates for cancer diagnosis and therapy

Info

Publication number
ZA894665B
ZA894665B ZA894665A ZA894665A ZA894665B ZA 894665 B ZA894665 B ZA 894665B ZA 894665 A ZA894665 A ZA 894665A ZA 894665 A ZA894665 A ZA 894665A ZA 894665 B ZA894665 B ZA 894665B
Authority
ZA
South Africa
Prior art keywords
immunoconjugates
therapy
cancer diagnosis
diagnosis
cancer
Prior art date
Application number
ZA894665A
Other languages
English (en)
Inventor
Michael G Rosenblum
G Rosenblum Michael
Renato Dulbecco
Dulbecco Renato
W Ross Allen
Ross Allen W
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of ZA894665B publication Critical patent/ZA894665B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA894665A 1988-07-07 1989-06-20 Immunoconjugates for cancer diagnosis and therapy ZA894665B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21659588A 1988-07-07 1988-07-07

Publications (1)

Publication Number Publication Date
ZA894665B true ZA894665B (en) 1990-04-25

Family

ID=22807704

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA894665A ZA894665B (en) 1988-07-07 1989-06-20 Immunoconjugates for cancer diagnosis and therapy

Country Status (18)

Country Link
US (1) US6669938B1 (xx)
EP (2) EP0423228B1 (xx)
JP (1) JP2756329B2 (xx)
KR (1) KR0152272B1 (xx)
AU (1) AU636113B2 (xx)
CA (1) CA1336497C (xx)
DE (1) DE68912334T2 (xx)
DK (1) DK175835B1 (xx)
ES (1) ES2059759T3 (xx)
FI (1) FI102517B (xx)
HK (1) HK1006676A1 (xx)
IE (1) IE62463B1 (xx)
IL (1) IL90688A (xx)
NO (1) NO303122B1 (xx)
NZ (1) NZ229652A (xx)
PT (1) PT91075B (xx)
WO (1) WO1990000405A1 (xx)
ZA (1) ZA894665B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ZA912490B (en) * 1990-04-19 1992-12-30 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
IE912716A1 (en) * 1990-08-14 1992-02-26 Res Dev Foundation Protein Structure of the Plant Toxin Gelonin
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
IT1286663B1 (it) * 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (ru) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1366067B1 (en) 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
AU2002327310B2 (en) 2001-07-17 2006-09-28 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
WO2003093443A2 (en) * 2002-05-03 2003-11-13 Raven Biotechnologies, Inc. Alcam and alcam modulators
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
AU2003298187B2 (en) 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
JP2007517506A (ja) 2004-01-05 2007-07-05 イーエムディー・レキシゲン・リサーチ・センター・コーポレーション 標的化用化合物
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101132813A (zh) * 2005-02-01 2008-02-27 研究发展基金会 靶向blys受体的blys融合蛋白和用于治疗b细胞增殖性疾病的方法
US7998737B2 (en) * 2006-09-12 2011-08-16 Deutsches Krebsforschungszentrum Cell culture of keratinocytes under non-differentiating conditions
GB0718045D0 (en) * 2007-09-14 2007-10-24 Peptcell Ltd Pharmaceutical compound
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
US4440747A (en) 1980-09-30 1984-04-03 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease
US4520226A (en) 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
GB2131830A (en) 1982-12-10 1984-06-27 Ludwig Inst Cancer Res Monoclonal antibody for use against breast cancer
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DK423483A (da) 1983-09-16 1985-03-17 Nordisk Laederforskningsraad Fremgangsmaade til maerkning af huder, skind og lignende arkformige materialer
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3408463C2 (de) * 1984-03-08 1987-02-26 Giulini Chemie Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung einer aluminium- und magnesiumhaltigen Verbindung der Formel Al↓5↓Mg↓1↓↓0↓ (OH)↓3↓↓1↓ (SO↓4↓)↓2↓ . x H↓2↓O
EP0184369B1 (en) * 1984-12-05 1992-04-01 The Salk Institute For Biological Studies Monoclonal antibody specific for a mammary tumor cell surface antigen
DE3581210D1 (de) * 1985-03-04 1991-02-07 Dana Farber Cancer Inst Inc Immunotoxin und herstellung.
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
JPS6220909A (ja) 1985-07-17 1987-01-29 株式会社井上ジャパックス研究所 パイプ等の接合方法
FR2587332B1 (fr) 1985-09-19 1989-02-17 Rhone Poulenc Spec Chim Procede de chloration selective de composes phenoliques
CA1287578C (en) 1985-12-06 1991-08-13 Michael J. Bjorn Anti-human ovarian cancer immunotoxins and methods of use thereof
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
EP0256471A3 (en) 1986-08-15 1989-10-25 Xoma Corporation Cytotoxic conjugates for cancer therapy
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography

Also Published As

Publication number Publication date
FI910049A0 (fi) 1991-01-04
EP0350230B1 (en) 1993-09-15
DK1091D0 (da) 1991-01-04
WO1990000405A1 (en) 1990-01-25
DE68912334T2 (de) 1994-05-05
IL90688A0 (en) 1990-01-18
FI102517B1 (fi) 1998-12-31
PT91075B (pt) 1995-01-31
EP0423228A4 (en) 1991-07-17
EP0350230A3 (en) 1990-12-12
JP2756329B2 (ja) 1998-05-25
FI102517B (fi) 1998-12-31
US6669938B1 (en) 2003-12-30
IE62463B1 (en) 1995-02-08
CA1336497C (en) 1995-08-01
NO303122B1 (no) 1998-06-02
DE68912334D1 (de) 1994-02-24
NO910031L (no) 1991-01-04
IL90688A (en) 1995-03-30
AU636113B2 (en) 1993-04-22
EP0423228B1 (en) 1994-01-12
DK175835B1 (da) 2005-03-21
PT91075A (pt) 1990-02-08
HK1006676A1 (en) 1999-03-12
NZ229652A (en) 1991-08-27
KR900701321A (ko) 1990-12-01
KR0152272B1 (ko) 1998-10-15
NO910031D0 (no) 1991-01-04
EP0423228A1 (en) 1991-04-24
AU3976189A (en) 1990-02-05
EP0350230A2 (en) 1990-01-10
IE891970L (en) 1990-01-07
ES2059759T3 (es) 1994-11-16
DK1091A (da) 1991-01-04
JPH04500510A (ja) 1992-01-30

Similar Documents

Publication Publication Date Title
HK1006676A1 (en) Immunoconjugates for cancer diagnosis and therapy
AU7813191A (en) Novel immunoconjugates and methods for their use in tumor therapy
GB2211709B (en) Multileaf collimator and related apparatus
EP0172721A3 (en) Use of phlorizin or its derivatives in the treatment of cancer
IL81759A0 (en) Mossbauer cancer therapy
IL77960A0 (en) Cancer therapy using mossbauer effect
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
EP0370115A4 (en) Catheter for diagnosis and therapy
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
EP0345356A4 (en) Platinum complex and therapeutic agent for malignant tumor
GB8804531D0 (en) Skin treatment formulations
AU2891389A (en) Diagnostic agent for breast cancer or tumor
ZA899631B (en) Cancer treatment
GB8813762D0 (en) Catechol derivatives for use in cancer treatment
SG115593G (en) Porphyrins and medicaments for cancer treatment
ATE99959T1 (de) Immunokonjugate fuer krebs-diagnose und -therapie.
GB8818556D0 (en) Novel therapeutic immunoconjugates for use in treatment of cancer
IL106658A0 (en) Cancer diagnosis and treatment
GB8700280D0 (en) Cancer treatment
GB8809045D0 (en) Therapeutic agent
IE894028L (en) Cancer treatment
GB8821120D0 (en) Therapeutic substance
AU3430189A (en) Compounds for diagnosis and/or therapy of tumours
GB9119081D0 (en) Cancer therapy and compositions for use therein
GB9201191D0 (en) Diagnostic and therapeutic compounds